

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

***Complete if Known***

<b>Application Number</b>	<b>10/623,737</b>
<b>Filing Date</b>	<b>August 11, 2003</b>
<b>First Named Inventor</b>	<b>Ellen Myra Dobrusin</b>
<b>Art Unit</b>	<b>1624</b>
<b>Examiner Name</b>	<b>Tamthom Ngo Truong</b>
<b>Attorney Docket Number</b>	<b>PC17310</b>

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	CITE NO. <sup>1</sup>	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
		2,949,466	08-16-1960	M. L. Hoefle, et al.	
		3,912,723	10-14-1975	M. W. Miller	
		3,939,084	02-17-1976	J. D. Sullivan	
		4,425,346	01-10-1984	M. Horlington	
		4,886,807	12-12-1989	N. Kitamura, et al.	
		6,084,095	07-04-2000	A. J. Bridges, et al.	
		6,150,373	11-21-2000	W. Harris, et al.	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	CITE NO. <sup>1</sup>	FOREIGN PATENT DOCUMENT COUNTRY CODE <sup>3</sup> NUMBER <sup>4</sup> KIND CODE <sup>5</sup> (IF KNOWN)	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T <sup>6</sup>
		WO 96/13262	05-09-1996	W. J. Thompson, et al.		
		JP 11-158180 (Patent Application)	06-15-1999	Masahiro Uehara		
		WO 99/61444	12-02-1999	E. M. Dobrusin, et al.		
		WO 00/24744	05-04-2000	W. Harris, et al.		
		WO 01/29041 A1	04-26-2001	J. P. Dunn, et al.		
		WO 01/29042 A1	04-26-2001	J. P. Dunn, et al.		
		WO 01/64679 A1	09-07-2001	J. L. Adams, et al.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

<b>Application Number</b>	<b>10/623,737</b>
<b>Filing Date</b>	<b>August 11, 2003</b>
<b>First Named Inventor</b>	<b>Ellen Myra Dobrusin</b>
<b>Art Unit</b>	<b>1624</b>
<b>Examiner Name</b>	<b>Tamthom Ngo Truong</b>
<b>Attorney Docket Number</b>	<b>PC17310</b>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ADACHI, K., "Synthesis of Orcinol Monomethyl Ether," <i>Memoirs of the Osaka Institute of Technology, Series A</i> , 1983, 33-42, vol. 28, no. 1.	
		CAPPUCCINO, J., et al., "Growth Inhibition of <i>Clostridium feseri</i> by Carcinostatic Purine and Pyrimidine Analogs – I. Effect of Medium on Growth Inhibition," <i>Cancer Research</i> , 1964, 1243-1248, vol. 24, no. 7.	
		CHATTERJEE, S., et al., "Synthesis of Some 4-Oxy & 2:4-Dioxypyrimido-(4,5-d)-pyrimidines," <i>Journal of Scientific &amp; Industrial Research</i> , 1958, 63-70, vol. 17.	
		CHATTERJEE, S., et al, "Synthesis of Some Pyrimido(4,5-d)Pyrimidines as Potential Purine Antagonists," <i>Journal of Scientific &amp; Industrial Research</i> , 1959, 272-278, vol. 18.	
		DEVI, N., et al, "Synthesis of Pyrimido [4,5-d] Pyrimidines as Antifungal Agents," <i>Indian Journal of Heterocyclic Chemistry</i> , 1998, 193-196, vol. 7.	
		EVERS, R., et al., "Zum Reaktionsverhalten der Thio-bis-formamidine; Versuche zur Synthese von Pyrimidino[4,5-d]pyrimidin-derivaten," <i>Z. Chem.</i> , 1980, 412-413, vol. 20.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

<b>Application Number</b>	<b>10/623,737</b>
<b>Filing Date</b>	<b>August 11, 2003</b>
<b>First Named Inventor</b>	<b>Ellen Myra Dobrusin</b>
<b>Art Unit</b>	<b>1624</b>
<b>Examiner Name</b>	<b>Tamthom Ngo Truong</b>
<b>Attorney Docket Number</b>	<b>PC17310</b>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GRABOYES, H., et al, "Pteridines. X. Some Pyrimidopyrimidine Isomers of Triamterene," <i>Pteridines</i> , 1968, 568-573, vol. 11.	
		GROHE, K., et al., "Synthese and Reaktionen von Pyrimido[4,5-d]pyrimidinen," <i>Liebigs Ann. Chem.</i> , 1974, 2066-2073.	
		GULEVSKAYA, A., et al., "Purines, Pyrimidines, and Condensed Systems Based on these Compounds," <i>Chemistry of Heterocyclic Compounds</i> , 1994, 1083-1086, vol. 30, no. 9.	
		GULEVSKAYA, A., et al., "Purines, Pyrimidines, and Condensed Systems Based on these Compounds," <i>Chemistry of Heterocyclic Compounds</i> , 1994, 1087-1091, vol. 30, no. 9.	
		HIROTA, K., et al., "A Facile Synthesis of 7-Substituted Pyrimido[4,5-d]-pyrimidine-2,4-diones," <i>Synthesis</i> , 1984, 589-590, vol. 1984, no. 7.	
		HIROTA, K., et al., "Novel Ring Transformations of 5-Cyanouracils into 2-Thiocytosines, 2,4-Diaminopyrimidines, and Pyrimido[4,5-d]pyrimidines by the Reaction with Thioureas and Guanidines," <i>Journal of the Chemical Society, Perkin Transactions 1</i> , 1990, 123-128, vol. 13.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

<b>Application Number</b>	<b>10/623,737</b>
<b>Filing Date</b>	<b>August 11, 2003</b>
<b>First Named Inventor</b>	<b>Ellen Myra Dobrusin</b>
<b>Art Unit</b>	<b>1624</b>
<b>Examiner Name</b>	<b>Tamthom Ngo Truong</b>
<b>Attorney Docket Number</b>	<b>PC17310</b>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MARSH, A., et al, "Self-Complementary Hydrogen Bonding Heterocycles Designed for the Enforced Self-Assembly into Supramolecular Macrocycles," <i>Chemical Communications</i> , 1996, 1527-1528, no. 13.	
		MASQUELIN, T., et al., "A Novel Solution- and Solid-Phase Approach to 2,4,5-Tri- and 2,4,5,6-Tetra-substituted Pyrimidines and Their Conversion into Condensed Heterocycles," <i>Helvetica Chimica Acta</i> , 1998, 646-660, vol. 81, no. 4.	
		REWCASTLE, G. W., et al., "Tyrosine Kinase Inhibitors. 5. Synthesis and Structure-Activity Relationships for 4-[(Phenylmethyl)amino]- and 4-(Phenylamino)quinazolines as Potent Adenosine 5'-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor," <i>Journal of Medicinal Chemistry</i> , 1995, 3482-3487, vol. 38, no. 18.	
		REWCASTLE, G. W., et al., "Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-Bromophenyl)amino]pyrido[d]-pyrimidines Are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor," <i>Journal of Medicinal Chemistry</i> , 1996, 1823-1835, vol. 39, no. 9.	
		SRIVASTAVA, S. K., et al., "A Solid Phase Approach to Substituted Pyrimidines and Their Conversion into Condensed Heterocycles for Potential Use in Combinatorial Chemistry," <i>Combinatorial Chemistry &amp; High Throughput Screening</i> , 1999, 33-37, vol. 2, no. 1.	
		TAYLOR, E., et al, "Pyrimido [4,5-d]Pyrimidines. Part I," <i>Journal of the American Chemical Society</i> , 1960, 5711-5718, vol. 82, no. 21.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)
**Complete if Known**

<b>Application Number</b>	<b>10/623,737</b>
<b>Filing Date</b>	<b>August 11, 2003</b>
<b>First Named Inventor</b>	<b>Ellen Myra Dobrusin</b>
<b>Art Unit</b>	<b>1624</b>
<b>Examiner Name</b>	<b>Tamthom Ngo Truong</b>
<b>Attorney Docket Number</b>	<b>PC17310</b>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		TOMINAGA, Y., et al., "Synthesis of Pyrimido[4,5-d]Pyrimidines," <i>Heterocycles</i> , 1979, 503-504, vol. 12. no. 4.	
		TOMINAGA, Y., et al., "Reaction of 6-Aminouracils with Ketenethioacetals," <i>Chemical and Pharmaceutical Bulletin</i> , 1984, 122-129, vol. 32, no. 1.	
		WAMHOFF, H., et al, "Pyrimido[4,5-d]Pyrimidines, Pyrimido[4',5':4,5]Pyrimido[6,1-a]-Azepines, and an Imidazo[5,1-f][1,2,4]Triazine by Three Component Reaction," <i>Heterocycles</i> , 1993, 1055-1066, vol. 35, no. 2.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.